Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is conducting a ...

They urge people to be wary of misinformation, like false claims on social media posts that hormones will prevent dementia ...

In this video from the American Society of Retina Specialists annual meeting, Charles C. Wykoff, MD, PhD, FASRS, discusses ...

A 68-year-old man with severe PAH and multiple coexisting conditions experienced marked improvement after receiving ...

I maintain a Strong Buy on Krystal Biotech, as the pause in melanoma trial enrollment is offset by promising progress in ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

Transthyretin amyloidosis (ATTR) is caused by the misfolding and aggregation of the transthyretin (TTR) protein, leading to multi-organ damage.